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A B S T R A C T
Sickle cell anemia (SCA) is a hereditary disorder that is characterized by tendency of hemoglobin
molecules within the erythrocytes to polymerize under hypoxia conditions, deform the red cells, and
promote vaso-occlusion and endothelial damage. This disease may be associated with the extracellular
release of nucleotides, particularly ATP, ADP and adenosine into the circulation. The aim of this study was
to investigate the possible changes in adenine nucleotides and nucleoside metabolizing enzymes as well
as their levels in serum of SCA patients. NTPDase, 50-nucleotidase and adenosine deaminase activities
were evaluated in serum obtained from blood samples of 15 SCA treated patients and 15 healthy subjects
(control group). The results revealed that there were significant (P < 0.001) elevations in NTPDase,
50-nucleotidase and ADA activities in serum of SCA treated patients when compared to the control group.
Furthermore, no significant (P > 0.05) alteration was observed in ATP, ADP and adenosine levels of both
SCA treated and control groups. However, inosine level was significantly (P < 0.05) decreased and
hypoxanthine level was higher in SCA treated patients (P < 0.001) when compared to the control group.
The results suggest the involvement of purinergic signaling enzymes in the maintenance of the levels of
extracellular nucleotides and nucleosides, thus preventing some pathophysiological conditions
associated with SCA.
© 2017 Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice. Published
by Elsevier Sp. z o.o. All rights reserved.
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Sickle cell anemia (SCA) is a hereditary disorder of hemoglobin
caused by a single missense mutation in the human b-globin gene
leading to an amino acid substitution (Glu ! Val) in the sixth
position of the b-globin chain. The polymerization results into HbS
abnormal hemoglobin under hypoxic conditions, induces a
mechanical distortion of red blood cells and indicates a key event
in the complex pathophysiology of SCA (Hebbel, 2011). It is a
chronic hemolytic anemia characterized by ongoing vaso occlu-
sion; persistent endothelial damage and progressive organ damage
(Fasano et al., 2015). Sickle cell disease may be associated with the
extracellular release of nucleotides and nucleoside, particularly* Author for correspondence: Universidade Federal de Santa Maria, Microbiologia
e Parasitologia, Avenida Roraima, 1000, Brazil.
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1214-021X/© 2017 Faculty of Health and Social Sciences, University of South Bohemia adenosine triphosphate (ATP), adenosine diphosphate (ADP) and
adenosine into the circulation (Jackson et al., 1996). ATP is as an
important extracellular messenger and a major metabolic currency
that is expended in cellular activities (Di Virgilio et al., 2009). In
healthy tissues, ATP is almost exclusively localized intracellularly
(Di Virgilio et al., 2009) but in pathological processes is released
from damaged cells and the concentration in the extracellular
space rises rapidly (Cekic and Linden, 2016).
ATP can be hydrolyzed by ectonucleotidases that are situated on
the surface of cells, in soluble forms in the interstitial medium or
within body fluids (Zimmermann et al., 2012). These circulating
soluble nucleotidases play significant role in controlling the
availability of ATP, ADP, AMP and adenosine in the extracellular
environment within physiological limits (Agteresch et al., 1999;
Zimmermann et al., 2012). An enzymatic cascade coordinates these
dual functions of removing one signal in the form of ATP and
generating another in form of adenosine (Agteresch et al., 1999).in Ceske Budejovice. Published by Elsevier Sp. z o.o. All rights reserved.
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human blood may serve as a promising diagnostic tool for cellular
damage in various pathophysiological conditions (Yegutkin,
1997).
Extracellular adenine nucleotides are hydrolyzed by series of
enzymes; nucleoside triphosphate diphosphohydrolase family
(NTPDases), nucleotide phosphate/phosphodiesterase family,
alkaline phosphatases and 50-nucleotidase. NTPDases hydrolyze
ATP and ADP while 50-nucleotidase hydrolyzes AMP to adenosine
(Zimmermann, 2000). Adenosine deaminase is another impor-
tant enzyme that is released to the extracellular space by
monocytes, macrophages and dendritic cells. It is responsible for
the deamination of adenosine to inosine (Zavialov et al., 2010).
Previous studies have demonstrated the presence of soluble
NTPDases, 50-nucleotidase and adenosine deaminase in rat blood
serum as well as in human blood (Doleski et al., 2016; Oses et al.,
2004; Yegutkin, 1997; Yegutkin et al., 2007). In addition, our
earlier reports have shown that these membrane-bound enzymes
may mediate and modulate purinergic system in lymphocytes
and platelets of sickle cell anemia patients (Castilhos et al., 2015,
2016). However, there is dearth of information on the activities
and levels of the soluble NTPDases in SCA. Thus, we speculated
that soluble NTPDases, 50-nucleotidase and adenosine deaminase
may also participate in the regulation of adenine nucleotides in
serum of SCA patients. To accomplish this, we investigated the
possible changes in adenine nucleotides and nucleoside metabo-
lizing enzymes as well as the levels of nucleotides and nucleo-
sides in serum of SCA patients.
Materials and methods
Chemicals
The substrates ATP, ADP, AMP, adenosine, as well as trizma
base, coomassie brilliant blue G and bovine serum albumin were
obtained from Sigma Chemical Co (St. Louis, MO, USA) and
K2HPO4was purchased from Merck (Darmstadt, Germany). All the
other chemicals used in this experiment were of the highest
purity.
Patients and samples
The samples consisted of 15 HbSS patients all in steady state
(SCA group) with a mean male age of 33 (range: 31–38 years old)
and mean female age of 26 (range: 18–51 years old). The control
group was consisted of 15 healthy subjects with a mean male age of
27 (range: 20–36 years old) and mean female age of 23 (range:
18–35 years old). The diagnosis of SCA was based on International
Statistical Classification of Diseases and Related Health Problems
(ICD 10) (D 57.0/57.1) (World Health Organization, 2015). All the
patients were currently receiving medications, such as folic acid
and hydroxyurea. These patients were using for treatment a dose of
5 mg per day and 35 mg/kg/day of folic acid and hydroxyurea (more
than 2 months of treatment), respectively. The subjects gave
written consent to participate in this study and the Human Ethics
Committee of the Health Science Center from the Federal
University of Santa Maria approved the project under the
registration number; 512.074. Subjects with altered blood pres-
sure, alcoholism, cigarette smoking or diagnostic of diabetes
mellitus, autoimmune disease and immunodeficiency were
excluded in this study. SCA patients who received blood
transfusion at least two months earlier were also excluded. In
this study, 15 SCA patients and 15 healthy control individuals were
chosen in line with a priori analysis using the G-power program
according to the method reported by Mayr et al. (2007).Isolation of blood serum fraction
The blood samples were collected in tubes without anticoag-
ulant and clots were formed. After the clot formation, the tubes
were placed in a centrifuge at 5000  g for 5 min at room
temperature. The resultant serum samples were aliquoted in
microtubes, placed in the refrigerator and subsequently used for
the assessment of enzyme activity and quantification of purine
levels.
Protein determination
Protein concentration was determined by the Coomassie Blue
method (Bradford, 1976), using bovine serum albumin as standard.
Determination of NTPDase and 50-nucleotidase activities
ATP and ADP hydrolyses were determined with slight
modifications (Oses et al., 2004). The reaction mixture containing
ADP or ATP as substrate (final concentration of 3.0 mM), 112.5 mM
Tris–HCl, pH 8.0, was incubated with approximately 1.0 mg of
serum protein at 37 C for 40 min in a final volume of 0.2 ml. The
reaction was stopped by the addition of 0.2 ml of 10% TCA. The
samples were chilled on ice and the amount of inorganic
phosphate (Pi) liberated was measured (Chan et al., 1986). In
order to correct the non-enzymatic hydrolysis, appropriate
controls were carried out by adding the serum after the reaction
was stopped with TCA. All samples were centrifuged at 5,000  g
for 5 min to eliminate precipitated protein and the supernatant
was used for the colorimetric assay. AMP hydrolysis was assessed
using a similar method described above for ATP and ADP
hydrolysis. The reaction mixture, containing 3.0 mM AMP as
substrate in 100 mM Tris–HCl, pH 7.5, was incubated with
0.5–1.0 mg serum protein at 37 C in a final volume of 200 ml.
All other procedures were the same as described above for ATP and
ADP hydrolysis. All samples were assayed in triplicate. Enzyme
activities were expressed as nanomoles of Pi released per min per
mg of protein.
Determination of ADA activity
ADA activity in serum was measured by spectrophotometric
method (Giusti and Gakis, 1971). Twenty-five microliters of serum
were used. The reaction was started by addition of 475 ml of 21 mM
adenosine as substrate and incubated for 1 h at 37 C. The reaction
was stopped by adding 1.5 ml of 106/0.16 mM phenol-nitroprus-
side to the reaction mixture, which was immediately mixed with
1.5 ml of 125/11 mM alkaline hypochlorite (sodium hypochlorite).
The ammonia released reacts with alkaline-hypochlorite and
phenol in the presence of a catalyst – sodium nitroprusside – to
produce indophenol (a blue color). The concentration of ammonia
is directly proportional to the indophenol and the absorbance was
read at 650 nm. Seventy-five micromolar of ammonium sulfate
was used as ammonium standard. The measurement was
performed in duplicate. The values of ADA activity in serum were
expressed as U/mg of protein.
In vitro effects of drugs used in the treatment of SCD patients on
determination of nucleotide hydrolysis
The in vitro effects of Folic acid and Hydroxyurea on NTPDase,
50-nucleotidase and ADA activities were evaluated. Serum from
health subjects were incubated with Folic acid and Hydroxyurea in
the medium reaction as previously described. The concentrations
of this drugs used in vitro were based on the mean plasma values of
the medications (Almeida et al., 2012).
Fig. 1. ATP (A) and ADP (B) hydrolysis by NTPDase in serum of SCA and control
patients. Enzyme specific activities were reported as nmol of Pi released/min/mg of
protein. Variables were expressed as mean  standard error of the mean (SEM). Bars
represent mean  S.E.M. (“***”) indicates a significant (P < 0.001) difference
between the SCA patients (n = 15) and control (n = 15). Student’s t-test for
independent samples was used for all the analyses.
Fig. 2. AMP hydrolysis by 50-nucleotidase in serum of control and patients with
SCA. Enzyme activity was reported as nmol of Pi released/min/mg of protein.
Variables were expressed as mean  standard error of the mean (SEM). Bars
represent mean  S.E.M. (“***”) indicates a significant P < 0.001, with n = 15
(controls) and n = 15 (SCA) (Student’s t-test for independent samples.).
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(HPLC)
Purine levels and metabolic residues of ATP hydrolysis of serum
samples were analyzed by HPLC. The denaturation of proteins was
performed using 0.6 mol/l perchloric acid. All samples were then
centrifuged (14,000  g for 10 min at 4 C), supernatants were
neutralized with 4.0N KOH and a second centrifugation (14,000  g
for 30 min at 4 C) was done. After second centrifugation, the
supernatants were collected and centrifuged again (14,000  g for
30 min at 4 C). 20 ml of aliquots were analyzed in a reversed-phase
HPLC (Shimadzu, Japan) using a C18 column (Ultra C18,
25 cm  4.6 mm  5 mm, Restek – USA). The elution was carried
out by applying a linear gradient from 100% solvent A (60 mM
KH2PO4 and 5 mM of tetrabutylammonium phosphate, pH 6.0) to
100% of solvent B (solvent A plus 30% methanol) over a 30 min
period (flow rate at 1.4 ml/min) (Voelter et al., 1980). The amounts
of purines were measured by absorption at 254 nm. The retention
time of standards was used as parameter for identification and
quantification. Purines concentrations were expressed as nmol of
compound per ml of serum.
Statistical analysis
The comparisons were performed using the Student’s t-test for
independent samples. The results are expressed as mean  stan-
dard error of the mean (SEM). Differences were considered
significant at P < 0.05. A priori analysis was used to determine
the necessary sample size N based on Mayr et al. (2007) report.
Results
General characteristics of the patients
Fifteen SCA patients consisting of five males with mean age of
33 (range: 31–38 years old) and ten females with mean age of 26
(range: 18–51 years old). These patients were placed on treatment
with doses of 5 mg per day and 35 mg/kg/day of folic acid and
hydroxyurea respectively. Fifteen healthy individuals with mean
age for males as 29 (range: 19–37 years old) and mean age for
females as 23 (range: 18–35 years old) formed the control group.
Determination of nucleotide hydrolysis
The results of the NTPDase activity in serum of patients with
SCA group and control groups are shown in Fig. 1. The hydrolysis of
ATP by serum NTPDase activity was significantly (P < 0.001) higher
in SCA patients (4.1 nmol of Pi/min/mg of protein; SEM = 0.5;
n = 15) when compared to the control group (1.4 nmol of Pi/min/
mg of protein; SEM = 0.5; n = 15) (Fig. 1A). Furthermore, the ADP
hydrolysis by serum NTPDase activity was significantly increased
in the SCA group (3.4 nmol Pi/min/mg; SEM = 0.5; n = 15; P < 0.001)
when compared to control group (1.3 nmol of Pi/min/mg of
protein; SEM = 0.5; n = 15) (Fig. 1B). In addition, the hydrolysis of
AMP by 50-nucleotidase activity in serum of patients with SCA and
control group is shown in Fig. 2. There was a significant elevation in
AMP hydrolysis in SCA group (0.55 nmol of Pi/min/mg of protein;
SEM = 0.12; n = 15; P < 0.001) when comparing to control group
(0.37 nmol of Pi/min/mg of protein; SEM = 0.09; n = 15).
ADA activity in serum
The results obtained for serum ADA activity are presented in
Fig. 3. Adenosine deaminase activity was higher in SCA group
(0.6 U/mg protein; SEM = 0.2; n = 15; P < 0.001) than control group
(0.3 U/mg protein; SEM = 0.1; n = 15).In vitro effects of drugs used in the treatment of SCD patients on
determination of nucleotide hydrolysis
Results obtained for the in vitro effects of NTPDase, 50-
nucleotidase and ADA activities showed that there were no
alterations in the activities of NTPDase, 50-nucleotidase and ADA
when folic acid and hydroxyurea drugs were used in the reaction
medium (P > 0.05, n = 15) (data not shown).
Fig. 3. Adenosine deamination in serum of control and patients with SCA. Enzyme
activities were reported as U/mg of protein. Variables were expressed as
mean  standard error of the mean (SEM). Bars represent mean  S.E.M. (“***”)
indicates a significant P < 0.001, with n = 15 (controls) and n = 15 (SCA) (Student’s
t-test for independent samples).
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Purine levels in serum were measured by HPLC and are shown
in Fig. 4. Levels of ATP, ADP, AMP and adenosine were not
significantly altered in SCA group when compared to control group.
However, the level of inosine was significantly decreased in SCA
group (0.4 nmol/ml; SEM = 0.1; n = 15; P < 0.05) when compared to
control group (0.9 nmol/ml; SEM = 0.2; n = 15). Conversely, there
was a significant (P < 0.001) increase in the level of hypoxanthine
in SCA group (25.2 nmol/ml; SEM = 1.5; n = 15) when compared to
the control group (9.5 nmol/ml; SEM = 0.5; n = 15).
Discussion
Pathologic conditions such as inflammation and ischemia occur
in sickle cell disease and are directly associated with the
extracellular release of nucleotides, particularly of ATP and ADP
(Jackson et al., 1996; Sun and Xia, 2013). Previous studies have
shown that elevated ATP levels may occur due to nucleotide release
from the red blood cells in response to low oxygen tension and
hemoglobin deoxygenation (Ellsworth, 2004; Ellsworth et al.,
1995). In addition, its levels and effects could be attenuated by
soluble NTPDase activity. To our best knowledge, this is the first
report where the relationship between adenine nucleotides
hydrolyzing enzymes and its levels in serum of SCA patients
was studied. Certain amounts of soluble NTPDase activity are
constitutively circulated in human bloodstream (Yegutkin et al.,
2007). In this study, the observed elevations in ATPase and ADPase
activities in serum of SCA patients may indicate the pathophysio-
logical conditions associated with SCA and the attempt to maintain
the ATP and ADP levels at physiological concentration (Ralevic and
Burnstock, 1998; Yegutkin et al., 2006). High concentrations of ATP
and ADP in the extracellular medium activate the pro-inflamma-
tory purinergic P2X7 receptors and contribute to tissue damage (Di
Virgilio, 1995), platelets induction aggregation and thrombus
formation, respectively (Puri, 1999).
These findings corroborate with previous results obtained from
our research group where increased E-NTPDase activity for ATP
and ADP hydrolyses were also observed in lymphocytes (Castilhos
et al., 2015) and platelets of SCA patients (Castilhos et al., 2016).
Soluble NTPDase enzyme may thus be fundamentally importance
as a diagnostic marker in SCA. In this study, the non-significant
change in ATP and ADP levels between SCA patients and healthy
individuals may suggest a compensatory mechanism initiated by
high ATPase and ADPase activity in serum in order to maintain
normal physiological concentrations of ATP and ADP in SCA
patients. Earlier studies have revealed that physiologicalconcentrations of extracellular nucleotides are usually in nano-
molar range under normal conditions (Yegutkin et al., 2006) and
the presence of high ATP concentrations are considered cytotoxic
(Ralevic and Burnstock, 1998).
Oses et al. (2004) reported that soluble NTPDase with
50-nucleotidase from rat blood serum may act by lowering ATP,
ADP and AMP, as well as increasing the concentration of adenosine,
which is a potent vasodilator. Besides the increased ATPase and
ADPase activities observed in this study, the AMPase activity was
also significantly higher in SCA patients when compared to healthy
subjects. This result agrees with the study of Mohamed et al.
(1993), where an increase in 50-nucleotidase activity in serum of
patients with sickle cell anemia was reported. The increased
AMPase activity observed in SCA patients may be a compensatory
mechanism that could be directly related to the amount of AMP
nucleotide produced by high ATPase and ADPase activity and
typified by the extracellular normal nanomolar range of AMP
measured by HPLC in this study. Cellular release of ATP/ADP may
result in feed-forward inhibition of 50-nucleotidase and delay of
extracellular adenosine formation until their extracellular levels
have been reduced to low micromolar levels by nucleotidases
(James and Richardson, 1993). The 50-nucleotidase catalyzes the
formation of adenosine from extracellular AMP and activation of
P1 adenosine receptors (Zimmermann, 1996). Adenosine is an
endogenous regulatory metabolite and inhibitor of platelet
aggregation (Galen et al., 1992). Adenosine released from different
cells or produced through the activity of cell surface ectoenzymes,
exerts its effects through the binding of four different G-protein-
coupled adenosine receptors. In platelets, binding of A2 subtypes
(A2A or A2B) leads to consequent elevation of intracellular cyclic
adenosine monophosphate, an inhibitor of platelet activation
(Johnston-Cox and Ravid, 2011).
ADA catalyzes the deamination of adenosine and deoxyadeno-
sine into their respective inosine nucleoside (Cristalli et al., 2001).
This conversion is an initial step in a series of reactions responsible
for lymphocyte proliferation and differentiation. Moreover, ADA is
considered an indicator of cellular immunity and fundamental for
the differentiation of lymphocytes (Blake and Berman, 1982). In
this study, the increased ADA activity observed in serum of SCA
patients may lead to a decrease in extracellular adenosine levels
and increase in extracellular inosine production. Increased
adenosine levels play a functional role in promoting sickling,
hemolysis and damage to multiple tissues in sickle cell disease
through the induction of 2,3-DPG in erythrocytes (Zhang et al.,
2011). Production of 2,3-DPG occurs only in RBCs and decreases the
oxygen binding affinity of hemoglobin (Sasaki and Chiba, 1983).
ADA may be a marker of inflammation during hypoxia and its
expression is increased in SCA (Eltzschig et al., 2006). The elevated
levels of adenosine in SCA patients observed in this study may be
attributed to the increased AMPase activity and could compensate
for the increased ADA activity observed in SCA. Our result follows
similar trend with previous investigation in our laboratory where
increased E-ADA activity was reported in lymphocytes and
platelets of SCA patients (Castilhos et al., 2015, 2016), reinforcing
the involvement and alterations of this membrane-bound and
soluble NTPDase as well as ADA activities in the pathophysiology of
SCA. This is also in agreement with the work of Silva-Pinto et al.
(2014) that observed HU-treated patients displayed increased ADA
activity, compared with untreated, indicating a novel mechanism
of action of HU mediated by the reduction of adenosine levels and
its effects on pathophysiological processes in SCA.
Adenosine level was observed to be regulated to the normal
level in the serum of SCA patients. However, the results obtained
for the HPLC analysis of other purine levels revealed that inosine
was significantly decreased while hypoxanthine level was elevated
in SCA. The reason for the alterations of these important purines
Fig. 4. Purine levels measurement in serum of SCA patients and control group. The purine levels were reported as nmol/ml. Bars represent mean  S.E.M. (“*”) and (“***”)
indicate a significant P < 0.05 and P < 0.001 respectively, with n = 15 (controls) and n = 15 (SCA) (Student’s t-test for independent samples).
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stated. The whole blood in humans including the red blood cell
(RBC) contains purine nucleoside phosphorylase (PNP); an enzyme
that converts inosine to hypoxanthine (Farthing et al., 2015).
Although, the PNP activity has not been investigated in this study,
we speculate that the increased PNP activity may probably have
facilitated the rapid breakdown of inosine to hypoxanthine and the
availability of hypoxanthine could play a pivotal role in reperfusion
injury associated with SCA (Rao et al., 1990).
In addition to the increased NTPDase, 50-nucleotidase and ADA
activities in SCA patients, we performed an in vitro study to verify if
treatment with folic acid and hydroxyurea could modify theseenzyme activities in SCA patients. The preliminary results do not
show that these drugs modify these activities. This may be
adjudged that these activities are solely from the enzymes present
on serum of SCA patients. The hypothesis of in vitro effects of the
two drugs analyzed was to check whether the drugs could modify
the activities of the enzymes in normal healthy individual. Hence,
results from our study show that these drugs do not modify the
activities of NTPDase, 50-nucleotidase and ADA in vitro in healthy
individuals. Although, we may not be able to categorically state the
effect of the drugs on the activities of NTPDase, 50-nucleotidase and
ADA activities in SCA in vitro, however, we observed that there was
a significant change in NTPDase, 50-nucleotidase and ADA activities
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subjects.
Conclusion
The results obtained in the present study revealed that the
alterations in soluble NTPDase, 50-nucleotidase, and ADA activities
in sickle cell disease, raising the possibility that purinergic
signaling is involved and altered in serum of SCA patients. Also,
the involvement of purinergic enzymes may be necessary in the
regulation of physiological concentrations of nucleotides and
nucleosides in serum of SCA patients. This is a preliminary study
and the role of the components of purinergic signaling in the
pathophysiology of sickle cell disease has been reported. However,
further studies are ongoing to assess the heterogeneity of the
clinical manifestation and response to HU and folic acid treatment.
In addition, we aim to explore the possible heterogeneity between
individual SCA patients as well as the polymorphisms of the
NTPDase, 50-nucleotidase and ADA genes and their receptors in
subsequent studies.
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